Journal Reviews
Incidence and outcomes of endophthalmitis with in-house compounded intravitreal bevacizumab injections
This multicentre study examining a five-year period from 2014 to 2018 evaluated the incidence rate and outcomes of endophthalmitis after intravitreal injection of in-house compounded bevacizumab. In-house compounded syringes were prepared in compounding pharmacy using sterile standard operating guidelines. All...
Refraction results in ROP with and without IVB
The authors aimed to compare refractive results of intravitreal bevacizumab (IVB) injection in premature neonates with retinopathy of prematurity (ROP) versus infants with spontaneous regression of ROP. The study included 87 infants (174 eyes). Group 1 included 38 infants (76...
Intravitreal bevacizumab vs. triamcinolone in patients with DMO at the time of cataract surgery
This prospective, single masked randomised control trial (RCT) compared visual and anatomical outcomes when either intravitreal bevacizumab (BVB) or triamcinolone (TA) was administered at the time of cataract surgery and at subsequent review, if required, in patients with diabetic macula...
Short-term effects of intravitreal bevacizumab on the cornea
Bevacizumab has been extensively used to treat macula oedema and neovascularisation of the retina and it has also been useful in the management of corneal neovascular diseases. This prospective study aimed to provide more information on the effect bevacizumab may...
